FOLD Stock Price – Quick Win: 75.49% in 1 Month

FOLD Stock Price

On October 27th of 2015, The I Know First algorithm gave signal of 9.55 for the ticker FOLD, which had a predictability indicator of 0.32. In accordance with the algorithm’s prediction, FOLD spiked 75.49% in 1 month from October 27th to November 27th.

FOLD Stock Price

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

In early October, Amicus Therapeutics shocked investors when it reported that it is delaying its timeline to file for FDA approval of Galafold, its promising new therapy for Fabry disease, until it collects additional data.

The revelation created uncertainty regarding Galafold’s peak sales potential that knocked shares down substantially, but investors appear to be warming back up to Amicus’ potential; particularly in Europe where a filing for approval earlier this year of Galafold could lead to a decision soon.

If approved, then Galafold could become an important new weapon used to combat Fabry disease, a tough-to-treat disease caused by an enzyme deficiency. Currently, Fabry disease is treated with enzyme replacement therapies (ERT) that are costly and thus generate hundreds of millions of dollars in annual sales for their drugmakers.

Business Disclosure: I Know First Research is the analytic branch of I Know First, a financial startup company that specializes in quantitatively predicting the stock market. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Read More From I Know First Research :

  • The Walt Disney Company: Beyond ESPN And Star Wars (View)
  • Now Boarding: American Airlines (View)
  • Visa Share Price is on the Rise (View)
  • For long Term Growth, Look No Further Than Gilead Sciences  (View)
  • Investing in World’s Greatest Killers Gives Amgen Enormous Upside potential (View)